Posted by Michael Wonder on 10 Nov 2020
Orphazyme submits European Marketing Authorisation application for arimoclomol for treatment of Niemann-Pick disease Type C
9 November 2020 - Follows U.S. FDA acceptance of new drug application with priority review in September 2020.
Orphazyme today announces it has submitted a marketing authorisation application to the EMA for its investigational product candidate arimoclomol for the treatment of Niemann-Pick disease Type C.
